chrM-7637-G-A
Position:
Variant summary
Our verdict is Likely benign. Variant got -1 ACMG points: 3P and 4B. PM2PP3BP6_Strong
The ENST00000361739.1(MT-CO2):c.52G>A(p.Glu18Lys) variant causes a missense change involving the alteration of a conserved nucleotide. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★★).
Frequency
Mitomap GenBank:
𝑓 0.0 ( AC: 2 )
Consequence
MT-CO2
ENST00000361739.1 missense
ENST00000361739.1 missense
Scores
Apogee2
Pathogenic
Clinical Significance
PD-risk-factor
Conservation
PhyloP100: 9.55
Genes affected
MT-CO2 (HGNC:7421): (mitochondrially encoded cytochrome c oxidase II) Contributes to cytochrome-c oxidase activity. Predicted to be involved in mitochondrial electron transport, cytochrome c to oxygen and positive regulation of vasoconstriction. Located in mitochondrial inner membrane. Part of respiratory chain complex IV. Biomarker of Huntington's disease and stomach cancer. [provided by Alliance of Genome Resources, Apr 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -1 ACMG points.
PM2
Very low frequency in mitomap database: 0.0
PP3
Apogee2 supports a deletorius effect, 0.5530385 >= 0.5 .
BP6
Variant M-7637-G-A is Benign according to our data. Variant chrM-7637-G-A is described in ClinVar as [Uncertain_significance]. Clinvar id is 439912.Status of the report is reviewed_by_expert_panel, 3 stars. We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=1, Uncertain_significance=2}.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
COX2 | COX2.1 use as main transcript | c.52G>A | p.Glu18Lys | missense_variant | 1/1 | YP_003024029.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MT-CO2 | ENST00000361739.1 | c.52G>A | p.Glu18Lys | missense_variant | 1/1 | ENSP00000354876 | P1 |
Frequencies
GnomAD4 exome Cov.: 0
GnomAD4 exome
Cov.:
0
We have no GnomAD4 genomes data on this position. Probably position not covered by the project.
Mitomap GenBank
AF:
AC:
2
Gnomad homoplasmic
AF:
AC:
3
AN:
56427
Gnomad heteroplasmic
AF:
AC:
3
AN:
56427
Alfa
AF:
Hom.:
Mitomap
PD-risk-factor
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:2Benign:1
Revision: reviewed by expert panel
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Mar 11, 2017 | - - |
Mitochondrial disease Uncertain:1
Uncertain significance, reviewed by expert panel | curation | ClinGen Mitochondrial Disease Nuclear and Mitochondrial Variant Curation Expert Panel, ClinGen | Jun 26, 2023 | The m.7637G>A (p.E18K) variant in MT-CO2 was reviewed by the Mitochondrial Disease Nuclear and Mitochondrial Variant Curation Expert Panel on June 26, 2023. There are no individuals or families with primary mitochondrial disease with this variant reported in the medical literature to our knowledge. This variant has been reported in one individual in the medical literature, in an individual with Parkinson disease with haplogroup Uk1 (PMID: 19076426). There are several occurrences in population databases. The frequency in the MITOMAP GenBank sequences is 2/59,389 (0.003%). The frequency in gnomAD v3.1.2 is 6/56,427 (0.011%). This includes three homoplasmic occurrences (two European, one African/African American, haplogroups T, J, L2) and three heteroplasmic occurrences (two European, one African/African American; haplogroups K, L3, U; one with 10-20% heteroplasmy, one with 30-40% heteroplasmy, one with 60-70% heteroplasmy; two individuals in 70-75-year-old range with details not provided on other individuals). The frequency in the Helix dataset is 16/195,983 (0.008%) including 12 homoplasmic occurrences (haplogroups T=6, H=3, A=1, C=1, L2=1) and four heteroplasmic occurrences (haplogroup J=1, K=1, L3=1, T=1). Therefore, the frequency of this variant meets neither criteria for pathogenicity (<0.002%) nor benign status (>0.5%). There are no cybrids, single fiber studies, or other functional assays reported for this variant. The computational predictor APOGEE gives a consensus rating of pathogenic with a score of 0.91 (Min=0, Max=1), which predicts a damaging effect on gene function (PP3). In summary, this variant meets criteria to be classified as uncertain significance for primary mitochondrial disease inherited in a mitochondrial manner. This classification was approved by the NICHD/NINDS U24 ClinGen Mitochondrial Disease Variant Curation Expert Panel on June 26, 2023. Mitochondrial DNA-specific ACMG/AMP criteria applied: PP3. - |
Leigh syndrome Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Wong Mito Lab, Molecular and Human Genetics, Baylor College of Medicine | Oct 17, 2019 | The NC_012920.1:m.7637G>A (YP_003024029.1:p.Glu18Lys) variant in MTCO2 gene is interpretated to be a Likely Benign variant based on the modified ACMG guidelines (unpublished). This variant meets the following evidence codes: BS4, BP6 - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Apogee2
Pathogenic
Hmtvar
Pathogenic
AlphaMissense
Pathogenic
BayesDel_addAF
Benign
T
DEOGEN2
Benign
T
LIST_S2
Benign
T
MutationAssessor
Pathogenic
H
MutationTaster
Benign
D
PROVEAN
Uncertain
D
Sift
Pathogenic
D
Sift4G
Uncertain
D
GERP RS
Varity_R
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at